Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGARD pharmacogenetic single-sample follow-up study
NL-OMON34629Phase 4Active, not recruiting
- Sponsor
- Merck Serono
- Start
- May 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of interferon beta-1a and glatiramer acetate in multiple sclerosis (MS) (2 arms), sponsored by Merck Serono. Primary endpoint: Association of SNP markers with treatment response. Started May 2010; status: active, not recruiting.
02
Drugs
interferon beta-1aglatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON34629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34629.